Backround: Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC). The HeCOG performed a multicenter phase II study of a weekly oxaliplatin administration schedule in patients with previously treated MCC to evaluate the antitumor efficacy and toxicity of this combination.
Introduction 5-Fluorouracil (5-FU) has been the mainstay of treatment in metastatic colorectal carcinoma (MCC) for more than 30 years. Biochemical modulation of 5-FU, mainly by the addition of folinic acid (FA), has been extensively investigated and is currently the standard treatment for MCC. However, a meta-analysis of randomized trials comparing 5-FU with 5-FU plus FA showed an increase in response rates in favor of the combination 5-FU plus FA, but with no difference in overall survival [1] .
Continuous intravenous administration of 5-FU increases the exposure time of tumor cells to 5-FU as well as the total tolerable dose over those of bolus administration. Continuous infusion (CI) of 5-FU is also associated with a lower incidence of neutropenia but with a higher incidence of mucositis and hand-foot syndrome [2] . CI of 5-FU with high-dose leucovorin appears to yield better response rates, especially if 5-FU is given as a short high-dose infusion. Weekly 24-hour 5-FU infusion allows the administration of very high doses of 5-FU at the beginning of the treatment, up to 10g/m 2 /month [3] .
Oxaliplatin (Eloxatin; Sanofi, France) is a novel platinum derivative with antitumor activity against a number of human and murine tumor cells both in vitro and in vivo, including colorectal cancer-derived cell lines [4] . As a single agent in phase II trials oxaliplatin demonstrated a 10% response rate with mild toxicity in patients with MCC and progressive disease while under therapy with fluoropyrimidines [5] . Oxaliplatin and 5-FU are synergistic both in vitro and in vivo [6] . A number of phase II trials have demonstrated the efficacy of oxaliplatin combined with 5-FU with and without FA in MCC that has failed 5-FU-based chemotherapy. The reported response rates vary between 25% and 45% [7] [8] [9] .
A retrospective analysis of the oxaliplatin dose intensity (DI) in the FOLFOX regimens (FOLFOX2 versus FOLFOX6) has demonstrated a dose intensity effect on the response rates. However, significant grade 3-4 neutropenia and neurotoxicity were associated with higher dose administration [10] . The concept of weekly oxaliplatin administration, although an empirical one, was based on the assumption of maintaining a dose intensity-response effect while trying to reduce systemic toxicity.
To date there are no reports in the literature on a weekly oxaliplatin administration schedule. In this phase II feasibility trial we evaluated the tolerability and activity of oxaliplatin combined with 5-FU and FA administered on a weekly schedule as salvage therapy in MCC.
Patients and methods
Patients with histologically confirmed and bidimensionally measurable metastatic adenocarcinoma of the colon and rectum were enrolled. Eligible patients included those who relapsed after or during chemotherapy with 5-FU and FA and/or irinotecan for advanced disease, but also those who received 5-FU and FA as adjuvant therapy but who relapsed during, or within six months after the completion of, therapy. Prior radiotherapy was allowed provided that measurable disease was outside the radiation fields. Patients had to have a WHO performance status (PS) of 0-2. Required laboratory parameters included: Baseline neutrophil count >1500/ul, platelet count > 100,000/ul, serum creatinine level <1.5 mg/dl, a serum AST or bilirubin level < 2 times the upper normal limit Ineligibihty criteria included prior cisplatin or paraplatin-containing chemotherapy, current history of chronic diarrhea, and a history of a second malignancy other than colorectal adenocarcinoma. The Scientific and Ethics Committees of all participating institutions approved the protocol. All patients signed an informed consent prior to study entry. Therapy consisted of Oxaliplatin at a dose of 50 mg/m 2 in 250 ml D5W as a two-hour single intravenous infusion followed by FA 500 mg/m 2 in 250 ml 0.9 normal saline as a two-hour infusion and 5-FU 2500 mg/m 2 as a 24-hour continuous infusion after the end of FA administration on days I, 8. 15, 22. 29, 36. The regimen was repeated every 50 days. A totally implantable central venous access device was put into place prior to therapy. Therapy was continued until disease progression or the occurrence of non-tolerable toxicity. All toxicity was graded according to the NCI Common Toxicity Criteria (CTC) and response was assessed according to WHO standards and confirmed by an independent reviewer. The use of Colony Stimulating Factors was not encouraged: they were employed only in instances of prolonged severe neutropenia during the previous cycle.
Carcinoembryonic antigen (CEA) and tumor measurements (by physical examination. CTscan or MRI) were performed within 14 days after registration and subsequently every 8 weeks (i.e.. every one cycle of therapy).
Time to event curves were estimated using the Kaplan-Meier method [11] . Survival was calculated from start of chemotherapy until death from any cause. Time to progression was determined by the interval between the initiation of therapy to the first date that disease progression was objectively documented, or treatment was discontinued. If no events had occurred by 1 June 1999, cases were censored. Fisher's exact test was used for testing relations of categorical \ariables [12] .
Sample size was based on response rate. According to Simon's tuo- stage minimax design, with a minimum expected response rate of 10% and an average expected response rate of 30%, a sample of 22 patients was required in the first step. If a minimum of three responses were observed it was planned to accrue a total of 33 patients. At the second phase, if at least seven responses occurred the probability of accepting an ineffective treatment would be 5%. On the other hand, the risk of rejecting a treatment with a response rate of more than 30% would be 10% [13] . Exact confidence intervals were used to determine the 95% upper and lower confidence limits of response rate.
Results
Between October 1997 and December 1998 a total of 32 patients, from three participating centers entered the trial. The patients' characteristics are shown in Table 1 . All patients were analyzed on the 'intent-to-treat' basis for response, toxicity and survival. All patients had been previously treated. Eight patients (25%) were adjuvant chemotherapy failures and twenty-four patients (75%) had progressed after receiving first-line chemotherapy.
Of these 24 patients, 17 had demonstrated disease progression under treatment, while the remaining 7 patients had disease stabilization. Six of these patients progressed within six months of completion of first-line chemotherapy. Twenty-two of the patients treated with firstline chemotherapy received a 5-FU/FA-based regimen and two were treated with CPT-11. Twenty-five (78%) patients received one and seven (22%) patients received two previous regimens. A total of 17 patients (53%) were symptomatic at baseline. The most common symptom was pain (38% of patients) related primarily to liver and osseous metastases. Other common symptoms included diarrhea, constipation and > 10% weight loss (10% each).
A total of 79 cycles (366 weeks) were administered to 32 patients. The median number of cycles was 2 (range 1-8). Most of the treatment-related delays occured during the first cycle. Six (5%) of the programmed weekly courses were administered with a delay of two weeks and seven (6%) courses with a delay of more than two weeks. The mean interval between courses during cycle 1 was 8.5 days. Per cycle most treatment-related delays were noted during the fourth and fifth weeks with a mean time interval between courses of 9 and 10 days, respectively ( Figure 1 ).
Thirty-nine cycles (50%) were administered with at least 90% of the planned dose of oxaliplatin with a median dose intensity of 33 mg/m 2 /week (range 24-43).
The incidence of main toxicities is summarized in Table 2 . Hematologic toxicity affected three patients (10%) with grade 3 neutropenia, and three patients (10%) with grade 3 and one patient (3%) with grade 4 thrombocytopenia. Diarrhea was the main non-hematologic toxicity. Twelve patients (38%) developed grade 3 and five patients (16%) grade 4 diarrhea. Due to this side effect only 23 cycles (29%) were given with at least 90% of the planned dose of 5-FU with a median dose intensity of 1517 mg/m 2 /week (range 974-2252). A total of 10 patients (32%) developed acute neurotoxicity primarily in the form of painful paresthesias and laryngopharyngeal dysesthesia. Only three of these patients had grade 2 toxicity. Eleven (35%) and five (16%) patients developed grades 1 and 2 neurotoxicity, respectively, in the form of sensory neuropathy which was mild and transient. At the end of treatment there was complete regression of the paresthesias. A significant increase in grade 2 neurotoxicity was seen at a higher cumulative dose of oxaliplatin. Thirty-six percent of patients who received a total (16) oxaliplatin dose of more than 1150 mg/m 2 developed grade 2 neurotoxicity versus 5% of patients who received less than 1150 mg/m 2 (/> = 0.024).
One patient developed angina pectoris possibly due to 5-FU during the third week of cycle 1, which responded to nitrates. One patient developed generalized pruritus during oxaliplatin infusion which resolved completely with antihistamines and corticosteroids. Three patients had to stop their therapy before the completion of cycle 1 and any signs of tumor progression due to treatment-related toxicity (one patient developed anemia grade 3, one patient diarrhea grade 3, while one patient had a severe episode of angina). Two patients (6%) died of sepsis, in one case of the urinary tract and in the other related to neutropenia.
When toxicity was assessed per cycle administered, by order of decreasing frequency, most common grade 3-4 toxicities included: diarrhea (26% of cycles), nausea and vomiting (13% of cycles), neutropenia and thrombocytopenia (5% of cycles), fatigue (4% of cycles), anemia (3% of cycles) and stomatitis, constipation (1% of cycles).
The objective response rate was 13% (95% confidence interval (95% CI): 3%-29%). All four responses were partial. Pretreatment characteristics for the responders included a baseline albumin level of at least 3.5 mg/dl, age < 55 years old (three patients), and a PS of 0 (three patients). One responder was 70 years old and another one had a PS of 2. Three patients had previously failed first-line and one adjuvant chemotherapy. All responders had parenchymal metastases (two in the liver and two in the lung) and received at least three cycles of treatment.
Twelve patients (38%) had stable disease and eight patients (25%) progressive disease. Eight patients (25%) were not assessed for response since they did not complete the first cycle. Of these, four were not assessed due to early death (prior to completion of cycle 1). Three patients discontinued treatment due to therapy-related toxicity, and one patient withdrew his consent during the first cycle. There was no difference in response rates between liver and lung metastases. In terms of symptomatic relief almost half of the patients who suffered from pain responded, as assessed by reduced need for analgesics.
After a median follow-up time of 15 months (range 0.5-17.5+), 22 patients (69%) have died. The median time to progression was three months and the median survival was nine months from the start of therapy. The Kaplan-Meier estimated probability of one-year survival for the group as a whole was 32%. Partial responses lasted for 4, 7.5, 8 and 14.5+ months. The median duration of disease stabilization was 5.5 months (range 2-15+). Twenty-five percent of the patients had stable disease lasting longer than seven months and 75% of the patients had stable disease lasting at least four months.
Discussion
During the past decade new agents with novel mechanisms of action and considerable activity against metastatic colorectal cancer have emerged. Among these new drugs, oxaliplatin appears to be active as first-as well as second-line therapy in patients refractory to fluoropyrimidines.
Oxaliplatin is a new platinum compound with no renal toxicity but with cumulative sensory neuropathy as the dose-limiting toxicity [14] . As a single agent Oxaliplatin has yielded a 10% response rate in previously treated patients, with a median time to progression of 6 months and a median survival of 14.5 months [3] . Oxaliplatin has demonstrated synergistic antitumoral activity with 5-FU and FA both in vitro and in vivo either as a chronomodulated or a flat schedule with overall response rates ranging between 25% and 58% and a complete response rate of 3.5%-5% [15] . These wide variations in response rates probably reflect differences in selection criteria as well as variations involving drug scheduling and timing between oxaliplatin and 5-FU.
In the present study we investigated a dose-intensive weekly schedule of oxaliplatin administration with a high dose of FA and 5-FU as a 24-hour continuous infusion. Toxicity was evaluated in all courses and results were given using the intent-to-treat method. The four partial responses lasted for 4, 7.5, 8, and 14.5+ months.
The response rate of 13% is significantly lower than other reported rates of oxaliplatin combined with highdose 5-FU/FA as a flat administration. This observation suggests that there might be a dose-intensity effect on the response rate. The equivalent DI of oxaliplatin in our study was 75 mg/m 2 /2 weeks. In the FOLFOX2 regimen (oxaliplatin DI: 100 mg/m 2 /2 weeks) the response rate was 46% [9] . In a study reported by Gamelin et al. oxaliplatin administered at a dose of 130 mg/m 2 every three weeks (dose intensity: 86 mg/m 2 /2 weeks) with weekly 5-FU and leucovorin, yielded a response rate of 37%. Finally, in a report of the results of the FOLFOX3 regimen (oxaliplatin DI: 85 mg/m 2 /2 weeks) the response rate fell to 20% (16) . The results from these and other phase II trials indicate a possible association between oxaliplatin DI and response, but this observation needs further confirmation. Despite the low overall response rate a significant percentage of patients (38%) achieved a stable disease status. When dealing with this particular cohort of patients, disease control (responses and stable disease) and survival is probably a better surrogate endpoint of activity, and in the present experience is as good as other published experiences. The reported median survival of nine months and one-year survival of 32% in the present study does not differ from those of a recently published randomized trial of patients with MCC failing 5-FU therapy treated with irinotecan versus best supportive care (nine months and 36%, for the irinotecan group versus seven months and 14% for the best supportive care group) [17] .
The median dose intensity of 5-FU was 1517 mg/m 2 / week, which compares favorably with that of other reported dose-intensive regimens [18] . Gastrointestinal toxicity was common with this schedule. Seventeen patients (53%) developed grades 3 or 4 diarrhea whereas most studies of combined oxaliplatin with 5-FU/FA report a less than 10% incidence of grade 3 or 4 diarrhea. The high percentage of severe diarrhea in the present study underlines the absolute need of a preceding phase I assessment. However, this toxicity was not unexpected considering the dose-intensive regimen and mode of administration of 5-FU used. Dose-intensive strategies are currently used in advanced colorectal cancer in an effort to increase response rates. However, severe toxic effects can be observed in treated patients. Recent studies have focused on 5-FU catabolic enzymes such as dihydropyrimidine dehydrogenase (DPD). DPD is subject to a genetic polymorphism and shows a wide range of individual variation [19] . There are several reports indicating a correlation between DPD deficiency and high plasma levels of 5-FU for protracted time periods resulting in severe, sometimes life-threatening, toxicity [20] . By assessing DPD levels in peripheral mononuclear cells with radioenzymatic assays, or by measuring the plasma dihydrouracil to uracil ratio, which appears to be a simpler technique, we can predict which patients are at increased risk of toxicity from 5-FU infusional therapy and therefore optimize 5-FUbased therapy [21] . In light of the high percentage of heavy diarrhea noted in our study, this information would be very useful.
Neurotoxicity in the form of sensory neuropathy was present in 50% of patients. There were no severe cases of acute neurologic toxicity (laryngopharyngeal dysesthesias or painful paresthesias) or any major functional impairment. The incidence and severity of neurotoxicity was lower than the rates reported in the literature. Andre et al. reported a 90% incidence of peripheral neuropathy using the bimonthly FOLFOX3 regimen (oxaliplatin at a dose of 85 mg/m 2 every two weeks) and De Gramont et al. reported a 94% incidence of peripheral neuropathy using the FOLFOX2 regimen (oxaliplatin at a dose of 100 mg/irr every two weeks) [9, 16] . The half-fold reduction of neurotoxicity observed in our study may be due to the different schedule of oxaliplatin administration since the dose intensity was similar. There were two cases of toxicity-related deaths, one from urinary sepsis and one from neutropenic sepsis. The latter case was associated with a significant delay in instituting antibiotic therapy (the patient lived in a remote area).
From this phase II trial it can be concluded that weekly administration of oxaliplatin in combination with high-dose FA and 5-FU did not result in significant therapeutic synergy against refractory colorectal cancer. However, cautious interpretation of the toxicity data suggests that the combination of a lower dose of 5-FU with oxaliplatin may limit the incidence of gastrointestinal toxicity and perhaps allow for an increase in the oxaliplatin dose-intensity in an attempt to increase response rates. In addition, the considerable number of patients who achieved a stable disease status cannot be ignored and if disease stabilization and overall survival are to be considered as primary endpoints this schedule is not inferior to other reported ones.
The role of oxaliplatin as a second-line agent in combination with 5-FU/FA needs further assessment. A number of ongoing phase II randomized trials are exploring oxaliplatin given every two or every three weeks in combination with several 5-FU modalities (bolus or continuous infusion, high or low dose, with FA modulation or not). Until then the combination of oxaliplatin with 5-FU should be regarded as a palliative tool for most patients with metastatic colorectal cancer who have failed therapy with 5-FU/FA.
